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Generation of sphingosine-1-phosphate by sphingosine kinases (SphKs) promotes allergic inflam-
matory diseases, but the roles of the individual SphK isoforms are unclear. Olivera et al. (2007)
show that SphK2 regulates mast cell activation whereas SphK1 enhances susceptibility to antigen
challenge in vivo.Sphingosine-1-phosphate (S1P) is re-
ceiving increasing scrutiny because of
its wide spectrum of activities, includ-
ing its influences on immune cell prolif-
eration, differentiation, survival, migra-
tion, and secretion (Rosen and Goetzl,
2005). It regulates lymphocyte traffick-
ing such as the egress of mature thy-
mocytes from the thymus and the mi-
gration of T cells within tissues and B
cells within the spleen. In addition, it in-
duces a bias toward a T helper 2 (Th2)
cell responses to enhance production
of IgE and IgE-mediated release of al-
lergic mediators from mast cells. In-
creased amounts of S1P in inflamed
tissues in immunologic diseases such
as asthma and rheumatoid arthritis
are thought to contribute to the patho-
genesis of these diseases. Hence, sys-
tems that regulate production and
actions of S1P are promising targets
for novel therapies for such diseases.
This prospect is enhanced by the dis-
covery that the immunosuppressant
drug FTY720 acts as a S1P mimetic
when converted to its phosphorylated
metabolite. FTY720 has proven to
be effective against autoimmune dis-
eases and transplant rejection without
inducing the side effects that are nor-
mally associated with systemic im-
munosuppression (Baumruker et al.,
2007).
The primary sources of S1P among
immune cells includemast cells, plate-
lets, and macrophages, although S1P
is produced in many types of nonim-
mune cells and circulates in blood
plasma. S1P is produced by phos-
phorylation of sphingosine through
the action of sphingosine kinases 1
(SphK1) or SphK2, neither of whichshare homology with any other lipid
kinase (Hait et al., 2006). S1P can be
converted back to sphingosine by
S1P phosphatase or can be eliminated
from the synthetic pathway by a S1P
lyase. SIP is thought to act within cells
primarily as a regulator of calcium ho-
meostasis, cell proliferation, and cell
survival (Hait et al., 2006). Although
there is considerable evidence for
S1P acting as an intracellular messen-
ger, the intracellular receptors or the
manner in which S1P is presented to
these receptors have yet to be defined.
S1P is also exported from cells and
can act extracellularly to stimulate,
for example, cell motility through spe-
cific G protein-coupled SIP receptors
of which five have been characterized,
namely, SIP1 through SIP5 (Hait et al.,
2006). The transporter of S1P in mast
cells has been identified only recently
as the multidrug resistance protein
(ABCC1), a member of the ‘‘C’’ branch
of the ABC transporter family (Mitra
et al., 2006). Studies with the ABCC1
inhibitor MK571 and knock down of
ABCC1 suggest that intracellular S1P
promotes degranulation whereas ex-
ported S1P stimulates chemotaxis in
mast cells (Mitra et al., 2006). ABCC1
thus provides another target for thera-
peutic or experimental intervention,
and inhibitory agents such as MK571
should help distinguish between the
intracellular and extracellular roles of
S1P (Figure 1).
Mast cells, the principal mediators
of acute allergic inflammatory reac-
tions, produce S1P after antigen stim-
ulation (Olivera and Rivera, 2005).
Much information has been gained
since the original reports that SphK,Immunityand in turn S1P, regulate calcium mo-
bilization (Choi et al., 1996) by a phos-
pholipase D-dependent mechanism
(Melendez and Khaw, 2002) in mast
cells. As depicted in Figure 1, mast
cells express SphK1 and SphK2, the
ABCC1 transporter, and the S1P re-
ceptors S1P1 and S1P2. In one model
(Olivera et al., 2006), both SphKs are
activated as a consequence of cross-
linking of the high-affinity IgE receptor,
Fc3RI, by antigen and the subsequent
activation of the Src kinases Lyn and
Fyn. Although Lyn and Fyn have com-
plementary roles in initiating signaling
cascades in mast cells, Fyn appears
to have the primary role in sustaining
the activation of the SphKs either
through the engagement of the adap-
tor protein, Gab2, phosphatidylinositol
3-kinase, and phospholipase D or
independently of this pathway, as in
the case of SphK2. The evidence for
these pathways comes from studies
with bone marrow-derived mast cells
(BMMCs) deficient in Lyn, Fyn, or
Gab2 and from pharmacologic stud-
ies. In thismodel, intracellular S1P pro-
motes calcium-dependent degranula-
tion whereas exported S1P can act
through the S1P1 receptor to promote
mast cell chemotaxis toward antigen
or the S1P2 receptor to augment de-
granulation (Jolly et al., 2004). Chemo-
taxis, but not degranulation, is blocked
by downregulation of ABCC1, MK571,
or pertussis toxin (Mitra et al., 2006).
There are several unresolved issues
with the above scheme. One is the rel-
ative importance of SphK1 and SphK2
in the activation of mast cells. The
second is the relationship of SphK
to phospholipase Cg in regulating26, March 2007 ª2007 Elsevier Inc. 271
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PreviewsFigure 1. Synthesis and Actions of S1P in Mast Cells
Crosslinking of Fc3RI-bound IgE by antigen results in activation of Lyn with the subsequent phos-
phorylation of Fc3RI immunoreceptor tyrosine-based activation motifs (blue boxes) and recruit-
ment of additional signaling elements that include Fyn. Fyn can activate SphK2 directly and
SphK1 indirectly through formation of a signaling complex that includes Gab2, phosphatidylinosi-
tol 3-kinase (PI3K), and phospholipase D (PLD), although the exact details are uncertain. The ac-
tivation of both SphKs leads to formation of S1P from sphingosine. SIP can act either within the cell
to mobilize calcium and thus promote degranulation and (not shown) production of eicosanoids
and cytokines or be exported via the ABCC1 transporter. The exported S1P can then act on the
G protein-coupled S1P receptors, S1P1 and S1P2, to stimulate chemotaxis and degranulation, re-
spectively. A distinguishing feature is that stimulation via SIP1 is selectively blocked by disrupting
Gai with pertussis toxin (PTX). The data of Olivera et al. (2007) suggest that S1P derived from
SphK1 and SphK2 are localized in separate pools or compartments, one of which is exported
via ABCC1 (SphK1 pool), and the other (SphK2 pool) acts internally tomobilize calcium and thence
regulate degranulation. Theoretically, degranulation could be further enhanced via S1P2 by extra-
cellular S1P of local or extrinsic origin, but the studies of Olivera et al. (2007) as well others suggest
that the S1P is largely of extrinsic origin.calcium mobilization. It was originally
proposed that S1P induced a rapid
transient calcium release from intra-
cellular stores (Choi et al., 1996)
whereas production of inositol 1,4,5-
trisphosphate by phospholipase Cg
induced a sustained release linked to
calcium entry after store depletion
(Melendez and Khaw, 2002). However,
intracellular S1P can induce calcium
entry in neutrophils and yeast. The
third is the contribution of extracellular
S1P, regardless of source, in the regu-
lation of degranulation. S1P concen-
trations in plasma are relatively high,
and S1P from extrinsic sources could
presumably alter mast cell responses.
Moreover, the recent studies of the
ABCC1 transporter suggest that ex-
ported S1P regulates mast cell che-
motaxis and not degranulation (Mitra
et al., 2006). Lastly, there is uncertainty
about the interaction of phospholipase
D with SphK. An variant of the model
shown (Figure 1) is that phospholipase272 Immunity 26, March 2007 ª2007 ElseD regulates SphK1 and that this iso-
form is the principal S1P-producing
enzyme in mast cells (Melendez and
Khaw, 2002).
In this issue of Immunity, Olivera
et al. (2007) resolve a number of these
issues by providing solid evidence that
SphK2 is the primary regulator of in-
tracellular signaling events whereas
SphK1 has the unexpected role of reg-
ulating concentrations of extracellular
S1P and, in turn, the sensitivity of
mast cells to antigen stimulation. Fetal
liver-derivedmast cells fromSphk1/,
Sphk2/, and Sphk1/Sphk2/
mice were examined because deletion
of both SphK genes is embryonically
lethal. Bone marrow-derived mast
cells (BMMCs) from Sphk1/ or
Sphk2/ mice were used for verifica-
tion of data. The experimental charac-
terization of each mast cell genotype
indicates that SphK2 is the predomi-
nant SphK and is the intrinsic regulator
of calcium influx and downstream cal-vier Inc.cium-dependent events such as acti-
vation of protein kinase C a and b,
NF-kB, degranulation, and production
of eicosanoids as well as cytokines.
SphK1, in contrast, appears to play
no role in these events. Further, neither
SphK appeared to influence the acti-
vation of MAP kinases. An important
detail was that although release of
calcium from intracellular stores and
activation of phospholipase Cg were
unaffected, calcium influx was se-
verely compromised in the absence
of SphK2. Apparently and contrary to
previous suggestions, SphK2 rather
than SphK1 regulates influx of cal-
cium, and neither one of the SphKs
regulate release of calcium from intra-
cellular stores. Insight as to the unex-
pected role for SphK1 and extracellu-
lar S1P came from studies of passive
systemic anaphylaxis in Sphk1/,
Sphk2/, Sphk1+/ Sphk2/, and
Sphk1/ Sphk2+/ mice. Circulating
amounts of S1P are primarily depen-
dent on SphK1 in cells other than
mast cells, and reduced circulating
amounts of S1P in Sphk1/ mice are
associated with reduced anaphylactic
response.
What are the implications of these
findings? It is now recognized that
the sensitivity of mast cells to antigen
challenge in vivo is highly dependent
on the environment in which they re-
side. Olivera et al. (2007) suggest that
the circulating amounts of S1P may
be one factor in determining whether
or not an allergic individual succumbs
to anaphylactic shock whereas others
with similar amounts of allergen-
specific IgE do not. If so, development
of inhibitors that selectively inhibit
SphK1 would be of therapeutic inter-
est given the multifaceted roles of the
SphKs in immunological processes.
In this regard, it would be of interest
to know whether SphK2 is the intrinsic
regulator in other immune cells and
could be left unscathed by a selective
SphK1 inhibitor.
The work of Olivera et al. (2007) now
provides a more coherent picture than
before, but there are still remaining is-
sues. Themechanism by which SphK2
regulates calcium influx is unknown
although Olivera et al. (2007) speculate
that stimulation of S1P formation by
SphK2 reduces the amounts of
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Previewssphingosine, which is known to inhibit
store-operated calcium release cal-
cium current (iCRAC). More definitive
evidence is needed for the link be-
tween phospholipase D and SphK1
(or SphK2). The mechanism by which
extracellular S1P enhances mast cell
responsiveness is not addressed by
Olivera et al. (2007), but extrapolation
of the data from studies of S1P recep-
tor-deficient BMMC (Jolly et al., 2004)
strongly suggest that it is through
S1P2. Finally, the findings of Olivera
et al. (2007) suggest that S1P derived
from SphK1 and SphK2 are segre-
gated in separate pools or compart-
ments, one of which is exported via
ABCC1 (SphK1 pool) and the other
(SphK2 pool) acts internally tomobilizeTim Protein Struc
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Tim molecules regulate T cell resp
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crystal structures of several Tim
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The recently discovered Tim (T cell
immunoglobulin mucin domain; also
known as TIM) family has emerged as
an important player in regulating T
cell responses. The Tim family con-
sists of eight members in mice (Havcr1
[Tim-1], Timd2 [Tim-2], Havcr2 [Tim-3],
Timd4 [Tim-4], three genes that are
predicted to encode Tims 5–7, and
Dppa 1 [Tim-8]; the proteins are also
referred to as mTIM-1, etc.) and three
members in humans (HAVCR1 [TIM-1],
HAVCR2 [TIM-3], and TIMD4 [TIM-4]).
In mice, the genes encoding Tim pro-
teins are encoded on mouse chromo-
some 11 in a genetic interval that has
shown linkage to a number of autoim-
mune diseases, allergy, and atopy ascalcium for cell activation. If so, this
raises challenging questions for future
research as to how S1P, with its highly
lipophilic chain, is segregated, trans-
ported within and outside the cell, and
appropriately presented to its targets.
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